Poor response to Eculizumab

Despite its great efficiency some patient do not properly respond to eculizumab. This poor response it mostly due to genetic variations in the complement C5 gene, but also other complement genes can be affected theoretically.

Systematic

Thrombotic microangiopathies
	Hemolytic-Uremic Syndrome
	Poor response to Eculizumab
		C5
	Thrombotic Thrombocytopenic Purpura

References:

1.	Nishimura J et al. (2014) Genetic variants in C5 and poor response to eculizumab.

2.	OMIM.ORG article Omim 615749